ONCOLOGY VENTURE
Oncology Venture ApS is a Danish Drug Development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed - to improve the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and through this improve success rates in Oncology Drug Development.
ONCOLOGY VENTURE
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2012-01-01
Address:
Hørsholm, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.oncologyventure.com
Total Employee:
1+
Status:
Closed
Contact:
+45 21 60 89 22
Email Addresses:
[email protected]
Total Funding:
6.2 M DKK
Technology used in webpage:
Google Apps For Business One.com DNS LogMeIn
Current Advisors List
Founder
Investors List
Seed Capital
Seed Capital investment in Venture Round - Oncology Venture
PreSeed Ventures
PreSeed Ventures investment in Venture Round - Oncology Venture
Official Site Inspections
http://www.oncologyventure.com
- Host name: webforward.webpod16-cph3.one.com
- IP address: 46.30.215.127
- Location: Copenhagen Denmark
- Latitude: 55.6786
- Longitude: 12.5589
- Timezone: Europe/Copenhagen
- Postal: 1052
More informations about "Oncology Venture"
Oncology Venture - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +45 21 60 89 22 Oncology Venture ApS is a Danish Drug Development company formed in 2012 dedicated to unlock the potential of …See details»
HOME | Oncology Ventures
Sebastian is a medical doctor from Australia and former public health consultant at the World Health Organization (WHO) in Geneva. Dr. Rositano previously studied finance as a Fulbright …See details»
Press release Oncology Venture signs agreement to
Jun 29, 2020 The core competency of the organization is expert consulting and full-service operations of complex clinical proof-of-concept trials and full development programs, …See details»
Oncology Venture appoints new CEO and CFO and proposes
Sep 4, 2019 Further, Mr. Carchedi took lead of Mallinckrodt Pharmaceuticals’ (NYSE: MNK) commercial organization and contributed to an IPO listing resulting in a market cap of USD 7.2 …See details»
Oncology Venture Information - RocketReach
Oncology Venture is a Drug Development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed drugs.See details»
Press release Oncology Venture acquires full ownership of
Jul 13, 2020 E-mail: [email protected] Telephone +45 53 63 96 37. About Oncology Venture A/S Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) …See details»
Press Release Oncology Venture Plans Name Change to Allarity ...
Hørsholm, Denmark (21 September 2020) – Oncology Venture A/S (“OV”) today announced that it will change its company name to Allarity Therapeutics (“Allarity” or the “Company”) and ...See details»
Press release Oncology Venture signs agreement to out-license …
Hørsholm, Denmark (29 June 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that it has signed a definitive agreement out-licensing two clinical pipeline assets ...See details»
Press Release Oncology Venture Plans Name ... - Associated Press …
Hørsholm, Denmark (21 September 2020) – Oncology Venture A/S (“OV”) today announced that it will change its company name to Allarity Therapeutics (“Allarity” or the “Company”) and will …See details»
Oncology Venture publishes the Annual Report for 2018
Mar 20, 2019 Press Release Hørsholm, Denmark and Cambridge, MA, US, March 20, 2019 – Oncology Venture A/S (“OV” or the Company) today publishes the Annual Report for 2018. …See details»
Oncology Venture | VentureRadar
Oncology Venture will utilize the technology and acquire product rights or co-develop with drug owners where OV’s technology can predict efficacy. ... Find out more about Oncology Venture, …See details»
Interview with Oncology Venture Sweden AB and Medical …
[email protected] or Peter Buhl Jensen, CEO Mobile: +45 21 60 89 22 E-mail: [email protected] About Oncology Venture Sweden AB Oncology Venture Sweden …See details»
Proposed merger between Medical Prognosis Institute and …
Sep 3, 2018 The Board of Directors of Oncology Venture considers the merger consideration to be fair from a financial point of view to its shareholders, and has obtained a fairness opinion …See details»
Oncology Venture appoints new Chief Financial Officer
E-mail: [email protected] Or Peter Buhl Jensen, CEO Mobile: +45 21 60 89 22 E-mail: [email protected] About Oncology Venture Sweden AB Oncology Venture Sweden …See details»
New date for registration of current rights issue - Allarity …
May 28, 2019 Press release Hørsholm, Denmark and Cambridge, MA, US, May 28, 2019 – Oncology Venture A/S today informs that the new shares subscribed for are expected to be …See details»
Company Announcement Oncology Venture publishes Interim …
The report is available as an attached document and on the company’s website (www.oncologyventure.com). Comment from CEO Steve Carchedi “Since mid-September, my …See details»
Press release Oncology Venture secures a US $5 million (50
May 6, 2020 E-mail: [email protected] Telephone +45 53 63 96 37. About Oncology Venture A/S Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) …See details»
Press release Oncology Venture acquires full control of Dovitinib …
Jun 8, 2020 Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) (“OV” or the “Company”) announced today that it has acquired the remaining 37% ownership in its priority …See details»
New date for the Annual General Meeting - Oncology Venture
E-mail: [email protected] Or Peter Buhl Jensen, CEO Mobile: +45 21 60 89 22 E-mail: [email protected] : About Oncology Venture Sweden AB. Oncology Venture Sweden …See details»
Oncology Venture US - PitchBook
Dec 30, 2016 Oncology Venture US General Information Description. Developer of medical therapeutics designed to treat cancer in women. The company's medical therapeutics includes …See details»